(secondQuint)Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV).

 This is designed to be a double-blind, placebo-controlled, randomized study.

 Approximately 30 participants will be randomized, dosed and followed.

 Participants will be randomly assigned to receive a single intravenous (IV) dose of MEDI-557 or placebo.

 Participants will be inoculated with RSV-A.

 Participants will be followed for efficacy for 12 days post-RSV challenge.

 Safety follow-up will be approximately 12 months from randomization.

.

 Intranasal Challenge of Healthy Adults With Respiratory Syncytial Virus (RSV)@highlight

The primary objective is to evaluate the suitability of the challenge model in measuring the efficacy of MEDI-557 compared to placebo in healthy adult participants for the reduction in the incidence of RSV through 12 days post-RSV challenge with the RSV Memphis-37 strain.

